Results 91 to 100 of about 45,216 (237)

Exosomal CircRNA-MANBA Mediates Hepatocellular Carcinoma Sorafenib Resistance via miR-1290/CD109/p-STAT3 Axis [PDF]

, 2023
Dingzhong Peng, Jiong Lu, Guilin Nie, Yaoqun Wang, Ningyuan Wen, Xianze Xiong, Bei Li, Nansheng Cheng   +7 more
openalex   +1 more source

Gankyrin‐Protein Interactions in GI Cancers: A Novel Target of New Therapeutics

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Gankyrin (PSMD10) is a 25 kDa oncogenic protein and regulatory subunit of the 26S proteasome, characterized by a sevenfold ankyrin repeat domain. Gankyrin is overexpressed in various malignancies, particularly gastrointestinal (GI) cancers. Gankyrin contributes to tumorigenesis by modulating key signaling pathways and engaging in oncogenic ...
Shuang Li, Yuky Lam, Aaron Muth, Zhe‐Sheng Chen, Shanzhi Wang   +4 more
wiley   +1 more source

Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism. [PDF]

, 2017
Malignant transformation is often accompanied by significant metabolic changes. To identify drivers underlying these changes, we calculated metabolic flux states for the NCI60 cell line collection and correlated the variance between metabolic states of ...
Bordbar, Aarash, Corbett, Austin J, Jamshidi, Neema, Palsson, Bernhard O, Thomas, Alex, Zielinski, Daniel C   +5 more
core   +1 more source

Nanomaterial‐Based Precision Medicine for Breast Cancer Diagnosis and Treatment

ChemNanoMat, EarlyView.
This research emphasizes the use of targeted precision medicine in the treatment of breast cancer. Through the integration of diagnosis and therapeutic delivery, nanocarriers are designed to selectively target cancer cells, preserving healthy tissue, thereby improving treatment effectiveness and reducing side effects.
Tanaka Ndongwe, Xavier Siwe Noundou, Gauta Gold Matlou, Stéphanie Bessoles, Johanne Seguin, Cyrille Richard, Nathalie Mignet, Yohann Corvis, Bwalya Angel Witika   +8 more
wiley   +1 more source

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. [PDF]

, 2014
Activating mutations in FLT3 confer poor prognosis for individuals with acute myeloid leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered by acquired resistance and ...
He, Bai-Liang, He, Bai-Liang, Lasater, Elisabeth A, Leung, Anskar Yh, Lin, Kimberly, Lopez, Michael S, Shah, Neil P, Shokat, Kevan M, Smith, Catherine C, Warkentin, Alexander A   +9 more
core  

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer [PDF]

, 2014
PURPOSE: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC).
A Berruti, A Bottini, A Bottini, A Calleri, A L Harris, A R Reynolds, C Foroni, C Isaacs, C Lindley, C Strina, CK Osborne, CK Osborne, D Andreis, D Generali, D Generali, D Generali, D Strumberg, D Strumberg, E Montagna, E Pasquier, F Ferrozzi, G Allevi, H Choi, H Huynh, H Turley, IE Smith, J Baselga, J Gligorov, JJ van der Hoeven, K Gatter, KS Albain, L Bazzola, L Gervot, LS Schwartzberg, M Bodini, M Dowsett, M Martinotti, M Milani, M R Cappelletti, MA Bonelli, MI Koukourakis, P G Petronini, P Gomez, P Le Goff, P Mancuso, PR Kelemen, R Bertoni, R Giardini, R Iyer, RI Nicholson, RI Nicholson, RN Keswani, S Aguggini, S B Fox, S Massarweh, S Mehta, S Venturini, SM Kumar, SR Johnston, SR Johnston, SX Yang, TK Chang, U Guller, V Zanoni, WJ Gradishar   +64 more
core   +4 more sources

MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7 [PDF]

, 2022
Xiaoning Feng, Bei Zou, Tianhao Nan, Xiaoxiao Zheng, Zheng Li, Jiahua Lan, Wei Chen, Jun Yu   +7 more
openalex   +1 more source

Living in interesting times - Challenging protein metabolism in the era of the epidemiological shift [PDF]

, 2016
The recently released results of the Global Burden of Disease, Injuries, and Risk Factor study 2013 reveal that during the past 23 years, metabolic and behavioral risk factors, including high BMI, increased their impact on global mortality and disability-
Laviano, Alessandro
core   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G, Matthay, Katherine K, Vo, Kieuhoa T   +2 more
core   +1 more source

TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p [PDF]

, 2021
Wei Song, Chuqian Zheng, Min Liu, Ying Xu, Yanyan Qian, Zhihong Zhang, Hongmeng Su, Xinxiu Li, Huazhang Wu, Pihai Gong, Yiping Li, Hong Fan   +11 more
openalex   +1 more source